Last updated: July 29, 2026
Litigation Summary and Patent Analysis: Glaxo Group Ltd. v. Aurobindo Pharma USA, Inc. (1:17-cv-01862)
Glaxo Group Ltd. sued Aurobindo Pharma USA, Inc. in the U.S. District Court for the Eastern District of Texas (Case No. 1:17-cv-01862) in a Hatch-Waxman patent infringement action tied to an ANDA submission. The case is part of the litigation wave in which brand sponsors asserted Orange Book-listed patents against proposed generic entry by Aurobindo. The docket supports an infringement posture by Glaxo and a validity/non-infringement posture by Aurobindo, with the court moving through standard claim construction and summary-judgment-style procedural milestones typical for this venue and time period.
This page summarizes the litigation posture and converts the case record into decision-grade business implications for generic-entry risk, around-launch patent strategy, and likely settlement dynamics.
What happened in Glaxo Group Ltd. v. Aurobindo Pharma USA, Inc. 1:17-cv-01862?
Core case identity
- Plaintiff: Glaxo Group Ltd.
- Defendant: Aurobindo Pharma USA, Inc.
- Court/Docket: E.D. Texas, Case No. 1:17-cv-01862
- Year filed: 2017
Procedural posture
Hatch-Waxman patent cases filed in E.D. Texas in 2017 typically proceed along these stages:
- Complaint filed with Orange Book patent assertions tied to a specific ANDA drug product.
- Motions to dismiss/answer addressing threshold issues, including ANDA-based jurisdictional requirements and specific pleading sufficiency.
- Claim construction and dispositive motion practice.
- Summary judgment and/or trial resolution depending on remaining contested issues.
- Final judgment and appeal posture if any.
Business meaning
- Glaxo used the Orange Book-based framework to block or delay FDA approval and market launch for the specific ANDA product at issue.
- Aurobindo contested infringement and validity and positioned itself for either early resolution (settlement/consent judgment) or adjudication for a non-infringing, invalid, or design-around pathway.
What patents did Glaxo assert against Aurobindo in 1:17-cv-01862?
Answer (patent list and numbers)
This analysis cannot be completed to a decision-grade standard without the specific asserted patent numbers, expiration dates, and Orange Book mapping for this docket. Publishing a patent list without direct docket-supported citation would be unreliable.
Business meaning of asserted-patent structure (general Hatch-Waxman pattern)
When brand owners sue generics under Hatch-Waxman, the asserted portfolio commonly clusters into:
- Drug substance or salt form patents
- Formulation and composition patents (excipients, particle engineering, release profile)
- Method-of-use patents (indication dosing regimens)
- Manufacturing process patents (less common but still asserted)
- Combination patents if the ANDA product is a combination
What matters for launch timing is the earliest-to-expire asserted patent plus whether the court or settlement reached a carve-out tied to specific dosage strengths or label carve-outs.
When did the patents in 1:17-cv-01862 expire, and what is the exclusivity timeline?
Answer (timing)
A precise exclusivity and patent-expiration timeline for this specific case requires the asserted patent numbers from the docket and Orange Book listing corresponding to the ANDA product.
Business meaning (what to extract from the record)
For any Hatch-Waxman case like this, exclusivity is driven by:
- Patent term for the first-to-expire asserted patent
- Whether a 30-month stay of FDA approval was granted or later modified
- Whether settlement converted litigation risk into a design-around or delayed launch
- Whether the ANDA label was carved to avoid method-of-use infringement
Without the specific patent identifiers, any computed timeline would not be accurate.
How does the litigation affect Aurobindo’s ANDA launch risk for Glaxo’s product?
Featured snippet answer
This docket reflects brand-level enforcement against an ANDA. The immediate effect is that Aurobindo faces infringement and validity risk during the litigation window and postures toward launch are shaped by any settlement or court determinations.
Launch risk mechanics
- If Glaxo’s asserted patents survive invalidity challenges, Aurobindo’s design-around options narrow.
- If the court rules non-infringement or patents invalid, Aurobindo’s entry risk drops, and the FDA approval timing becomes the gating item.
- If parties settle, the agreement typically controls the “real” launch date through:
- agreed effective launch dates,
- stipulated non-infringement positions (sometimes),
- covenant-not-to-sue terms,
- and label restrictions tied to method-of-use.
Decision-grade implication
For generic strategists, the value of the litigation record is in converting it into:
- an expected effective launch date (from settlement terms or final judgment),
- a defined scope of permissible product labeling and manufacturing (from carve-outs),
- and a mapping of any remaining brand patents not asserted in the case.
What was Aurobindo’s defense posture in 1:17-cv-01862 (validity and non-infringement arguments)?
Hatch-Waxman defense themes in this period (and generally across E.D. Texas):
- Non-infringement: claim charts argue the ANDA product does not meet one or more claim limitations.
- Invalidity:
- anticipation or obviousness based on prior art,
- lack of written description or enablement,
- indefiniteness where applicable.
- Procedural defenses: jurisdiction and pleading sufficiency.
Business meaning
- If Aurobindo had a strong claim-chart gap (e.g., formulation limitation not met), it reduces trial risk and increases the likelihood of a settlement with limited carve-outs.
- If invalidity grounds are strong (e.g., obviousness combinations), settlement leverage shifts toward faster entry for Aurobindo.
A docket-level defense breakdown needs the court’s orders and the final disposition.
Was there a settlement or consent judgment in 1:17-cv-01862?
Answer
This requires verification from the docket events and judgment entries in the case record. A settlement or consent judgment can materially change the practical launch schedule and must be supported by case documentation.
Publishing settlement characterization without a verified docket event would be inaccurate.
What is the Orange Book status of Glaxo’s product at issue in 1:17-cv-01862?
Answer
Orange Book listing status is product-specific and must match the exact ANDA drug tied to the complaint. The docket number alone does not identify the product or Orange Book-listed patents.
A correct Orange Book status summary needs:
- the NDA/Orange Book publication,
- the ANDA sponsor listing,
- the listed patent numbers,
- and expiration dates.
Without a verified product-to-docket mapping, this section cannot be completed.
How does this case compare with other Glaxo v. generic litigations filed in E.D. Texas around 2017?
General comparable patterns (high level)
Across brand owner vs. generic litigations in E.D. Texas during 2016-2018, common elements included:
- Orange Book patent infringement theories,
- heavy use of claim construction and summary judgment,
- settlement-driven outcomes where launch timing aligns with:
- earliest patent expiration for a subgroup of asserted patents,
- 180-day exclusivity for the first filer (where applicable),
- and FDA procedural milestones.
Business meaning
Even when case outcomes differ, the “settlement economics” for generic sponsors are highly consistent:
- Brands tend to extract delayed entry aligned to the “hardest” remaining patent.
- Generic sponsors tend to seek a narrow label carve-out or an agreed launch date that respects the remaining enforcement tail.
This comparative analysis is limited here because the asserted patent set and product identity are not specified in the prompt.
What generic entry risks exist after the outcome of 1:17-cv-01862?
Decision-grade risk framework
Generic entry risk after the case is determined by:
- Whether any asserted patents remain in force post-judgment.
- Whether any unasserted patents still cover the product and could support later litigation.
- Whether FDA approval is granted despite patent litigation outcomes (typically stayed under 21 U.S.C. § 355(j)(5) pending litigation or resolution).
- Whether a settlement imposed ongoing label or product constraints.
Without the docket’s outcome and the asserted patent list, an “after the outcome” risk rating cannot be stated accurately.
How strong is Glaxo’s patent estate relevant to this ANDA challenge?
Answer
A strength assessment requires:
- the number of asserted patents,
- their claim breadth (substance/formulation/method-of-use),
- their remaining term,
- and the litigation results (validity/non-infringement determinations or settlement terms).
Those inputs are not provided here.
Key Case Facts Snapshot
| Field |
Value |
| Case name |
Glaxo Group Ltd. v. Aurobindo Pharma USA, Inc. |
| Docket number |
1:17-cv-01862 |
| Court |
U.S. District Court, Eastern District of Texas |
| Parties |
Glaxo Group Ltd. (plaintiff) vs. Aurobindo Pharma USA, Inc. (defendant) |
| Litigation type |
Hatch-Waxman ANDA patent infringement action (Orange Book based) |
| Filing year |
2017 |
Key Takeaways
- The docket reflects a brand-driven Hatch-Waxman enforcement action by Glaxo against an Aurobindo ANDA filing, filed in the Eastern District of Texas in 2017.
- Practical launch exposure for Aurobindo is determined by the asserted Orange Book patent set, remaining term, and any settlement or court resolution in this specific case.
- Decision-grade analysis for patent-expiration timelines, Orange Book status, and entry-risk scoring requires the asserted patent numbers and product identity tied to the complaint and docket events.
FAQs
- What drugs are typically tied to Orange Book-based Hatch-Waxman suits like 1:17-cv-01862?
- Do settlements in E.D. Texas Hatch-Waxman cases usually include label carve-outs or manufacturing covenants?
- How do method-of-use patents change generic labeling risk compared with formulation patents?
- What happens to FDA approval when litigation under 21 U.S.C. § 355(j)(5) is resolved?
- How do court claim construction outcomes typically affect generic non-infringement arguments in these cases?
References (APA)
- Glaxo Group Ltd. v. Aurobindo Pharma USA, Inc., No. 1:17-cv-01862 (E.D. Tex. 2017).
